Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension

Article Abstract:

The effectiveness of cilazapril was compared to that of hydrochlorothiazide in the treatment of 169 patients, aged 18 to 75 years, with mild to moderate essential hypertension, or abnormally high blood pressure of unknown cause. Sitting diastolic blood pressure is the pressure during the relaxation phase of the heart contraction cycle and is measured while the patient is sitting. A dose of 2.3 milligrams (mg) cilazapril decreased sitting diastolic blood pressure by about 15 millimeters mercury (mm Hg), whereas 25 mg of hydrochlorothiazide decreased sitting diastolic blood pressure by about 13 mm Hg. Cilazapril therapy was associated with 21 adverse events, whereas treatment with hydrochlorothiazide was associated with 32 unfavorable incidents. Three patients withdrew from cilazapril treatment because of mild angioedema, a skin disorder, headaches and chest pain, whereas three patients stopped hydrochlorothiazide treatment because of dizziness, fatigue, and stomach bleeding. Hydrochlorothiazide caused several changes in blood chemistry including a decrease in potassium and increase in cholesterol, whereas cilazapril had no adverse biochemical effects. The results demonstrate that cilazapril reduced blood pressure to the same extent as hydrochlorothiazide, and was also more effective in young patients. Cilazapril is an effective and safe agent for treating mild to moderate hypertension. (Consumer Summary produced by Reliance Medical Information, Inc.)

Hydrochlorothiazide

---

Efficacy and safety of cilazapril in elderly patients with essential hypertension, a multicenter study

Article Abstract:

The effectiveness and safety of the angiotensin-converting enzyme (ACE) inhibitor cilazapril was evaluated in 83 elderly patients with essential hypertension, or abnormally high pressure of unknown cause. The sitting diastolic blood pressure is the pressure during the relaxation phase of the heart contraction cycle and is measured when the patient is sitting. The sitting diastolic blood pressure was about 102 millimeters of mercury (mm Hg) before treatment with cilazapril, and decreased by an average of 13 mm Hg after treatment for 12 weeks. The sitting diastolic pressure was decreased by 10 mm Hg or more in 75 percent of patients given cilazapril, and recovered to normal values in 60 percent of the patients. Three patients had large decreases in blood pressure after only one dose of cilazapril, and none had clinical symptoms. Fourteen patients complained of unfavorable side effects, which were unrelated to drug therapy. Four patients with underlying diseases experienced serious complications, including angina pectoris (chest pain), arrhythmia (abnormal heart rhythm), blood pressure elevation, and myocardial infarction (heart attack), but these effects were not clearly related to cilazapril therapy. The results indicate that cilazapril was an effective, safe and well-tolerated treatment for hypertension in elderly patients. (Consumer Summary produced by Reliance Medical Information, Inc.)

Demographic aspects, Essential hypertension

---

Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor

Article Abstract:

The new angiotensin-converting enzyme (ACE) inhibitor cilazapril, which lacks a sulfhydryl or sulphur-hydrogen group, has been tested for its effectiveness in treating hypertension, or abnormally high blood pressure. About 450 patients received cilazapril for more than one year, and another 430 patients were given cilazapril combined with another antihypertensive agent, hydrochlorothiazide, for more than six months. After eight weeks of treatment, doses of 2.5 and 5.0 milligrams per day of cilazapril were as effective as hydrochlorothiazide, atenolol, propranolol, captopril, and enalapril, which are other currently used antihypertensive drugs. Patients receiving cilazapril had the same number of side effects as patients who were not receiving antihypertensive treatment, suggesting a very low incidence of adverse effects with cilazapril. This new antihypertensive agent was better tolerated than hydrochlorothiazide and atenolol. Adverse effects of cilazapril included headache, dizziness, fatigue, nausea, and chest pain, and occurred with an incidence of one percent. The results demonstrate that cilazapril is both an effective and well-tolerated treatment for patients with hypertension. (Consumer Summary produced by Reliance Medical Information, Inc.)

Similar abstracts:

• Abstracts: Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease. In vitro activity of ofloxacin against Chlamydia trachomatis
• Abstracts: Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol: a multicenter study
• Abstracts: Epidemiology and evaluation: steps toward hypertension treatment in the 1990s. Conclusion

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.